EA202092959A1 - PHARMACEUTICAL AGENT FOR THE TREATMENT OF ARTHROLOGICAL DISEASES - Google Patents

PHARMACEUTICAL AGENT FOR THE TREATMENT OF ARTHROLOGICAL DISEASES

Info

Publication number
EA202092959A1
EA202092959A1 EA202092959A EA202092959A EA202092959A1 EA 202092959 A1 EA202092959 A1 EA 202092959A1 EA 202092959 A EA202092959 A EA 202092959A EA 202092959 A EA202092959 A EA 202092959A EA 202092959 A1 EA202092959 A1 EA 202092959A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
arthrological
pharmaceutical agent
diseases
arthrological diseases
Prior art date
Application number
EA202092959A
Other languages
Russian (ru)
Inventor
Николай Наумович Беленький-Гордонов
Original Assignee
Общество с ограниченной ответственностью "ДИАМЕД-фарма"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "ДИАМЕД-фарма" filed Critical Общество с ограниченной ответственностью "ДИАМЕД-фарма"
Publication of EA202092959A1 publication Critical patent/EA202092959A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Изобретение относится к области медицины, в частности к лекарственным средствам для лечения артрологических заболеваний. Изобретение представляет собой средство для лечения артрологических заболеваний, включающее эффективное количество хондроитина сульфат натрия и по меньшей мере одно вспомогательное вещество или носитель, отличающееся тем, что дополнительно содержит металлическое или коллоидное серебро в относительном количестве от 0,10 до 10 мг/кг в пересчете на массу хондроитина сульфат натрия. Средство по изобретению обладает стабильностью в течение длительного времени и/или при эксплуатации ввиду отсутствия микробной контаминации, с сохранением эффективности и безопасности.The invention relates to medicine, in particular to medicines for the treatment of arthrological diseases. The invention is an agent for the treatment of arthrological diseases, comprising an effective amount of chondroitin sodium sulfate and at least one excipient or carrier, characterized in that it additionally contains metallic or colloidal silver in a relative amount from 0.10 to 10 mg / kg in terms of mass of chondroitin sodium sulfate. The agent according to the invention is stable for a long time and / or during operation due to the absence of microbial contamination, while maintaining efficiency and safety.

EA202092959A 2020-05-27 2020-12-28 PHARMACEUTICAL AGENT FOR THE TREATMENT OF ARTHROLOGICAL DISEASES EA202092959A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020117485A RU2739747C9 (en) 2020-05-27 2020-05-27 Pharmaceutical agent for arthritic diseases treatment

Publications (1)

Publication Number Publication Date
EA202092959A1 true EA202092959A1 (en) 2021-11-30

Family

ID=74106425

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092959A EA202092959A1 (en) 2020-05-27 2020-12-28 PHARMACEUTICAL AGENT FOR THE TREATMENT OF ARTHROLOGICAL DISEASES

Country Status (2)

Country Link
EA (1) EA202092959A1 (en)
RU (1) RU2739747C9 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2284181C2 (en) * 2004-11-11 2006-09-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Федерального агентства по здравоохранению и социальному развитию (ФГУ "МНТК"МГ"им. акад. С.Н. Федорова Росздрава") Pharmaceutical composition for prophylaxis of ophthalmological infections
US20080227747A1 (en) * 2007-03-15 2008-09-18 Tabbiner Philip Composition and methods for treating or preventing degenerative joint and cardiovascular conditions
RU2413503C2 (en) * 2009-02-11 2011-03-10 Сергей Иванович Воробьёв Perfluorocarbon emulsion with colloidal silver for medicobiological and cosmetic application: composition and administration means
RU2458693C1 (en) * 2011-07-28 2012-08-20 Валентин Антонович Виноградов Lyophilised pharmaceutical composition for preparing solution for injections for treating degenerate-dystrophic locomotor diseases and method for preparing it
RU2547572C2 (en) * 2013-07-04 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Pharmaceutical composition for treating joint and bone tissue diseases
RU2580589C1 (en) * 2015-01-27 2016-04-10 Общество с ограниченной ответственностью "ДИАМЕД-фарма" Method of preparing injection form of chondroitin sulphate

Also Published As

Publication number Publication date
RU2739747C1 (en) 2020-12-28
RU2739747C9 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
AR105712A1 (en) QUICK ACTION INSULIN COMPOSITIONS
DE69731610D1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
NI201100147A (en) METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS.
MX2019012884A (en) Combination therapy.
RU2008119454A (en) MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
BR112012030641A2 (en) methods and compositions for oral pharmaceutical therapy
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
PH12020550775A1 (en) Pentosan polysulfate and medicine containing pentosan polysulfate
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
AR062779A1 (en) TREATMENT OF MULTIPLE SCLEROSIS (MS)
PE20031047A1 (en) TREATMENT OF POST-MENOPAUSAL PATIENTS IN PATIENTS WITH BREAST CANCER
EA202092959A1 (en) PHARMACEUTICAL AGENT FOR THE TREATMENT OF ARTHROLOGICAL DISEASES
AU2022373595A1 (en) Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
MX2018000963A (en) Synergistic pharmaceutical composition originated from the active enantiomer s-ketorolac tromethamine and tramadol hydrochloride.
EA202092960A1 (en) PHARMACEUTICAL AGENT FOR THE TREATMENT OF ARTHROLOGICAL DISEASES
EA202092958A1 (en) PHARMACEUTICAL AGENT FOR THE TREATMENT OF ARTHROLOGICAL DISEASES
CR20220620A (en) Aqueous pharmaceutical composition of levilimab
MX2022013722A (en) Cysteamine for the treatment of sars-cov-2 infection.
JOP20220104A1 (en) Dosing regimen for anti-dll3 agents
MX2022012001A (en) Preventative treatment of migraine.
WO2020139163A3 (en) Combination of antiviral agents
MX2021002936A (en) Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease.
BR112021018994A2 (en) Low dose triple combination formulation